Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic SanaCutan cream for prevention of atopic dermatitis in high-risk newborns
2024-513289-21-00Phase 3Completed
- Sponsor
- InfectoPharm
- Start
- Jan 2020
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SanaCutan Basiscreme in atopic dermatitis (AD) (2 arms), sponsored by InfectoPharm. Primary endpoint: Cumulative incidence of confirmed atopic dermatitis at 6 months. Started Jan 2020; status: completed.
02
Drugs
SanaCutan Basiscreme
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2024-513289-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513289-21-00.